Anko Bio: Boshengji obtains implicit approval for drug clinical trials

2025-04-24 18:29:32

Anko Bio announced that the UTAA09 injection jointly developed by Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anko Cell Technology Co., Ltd., in which the company holds a stake, has obtained implicit approval from the Center for Drug Evaluation of the National Medical Products Administration. The drug is the world's first generic off-the-shelf CD19-UCAR-Vδ1T cell product approved for clinical trials, and is indicated for adult relapsed/refractory acute B-lymphocytic leukemia (B-ALL).

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Apple (AAPL.O): Vietnam is expected to be the country of origin for most iPads, Macs, Apple Watches and Airpods sold in the United States.
                            2025-05-02

                                    US judge rules Apple violated order to reform App Store
                            2025-05-01

                                    Shanghai: Using tax support to encourage more innovation and help companies go global
                            2025-04-30

                                    Ideal Auto's Ring OS is officially open source, and the code is now available for download
                            2025-04-28

                                    Apple (AAPL.O) had a net profit of US$24.78 billion in the second quarter of fiscal year 2025, compared with market expectations of US$24.26 billion and US$23.636 billion in the same period last year.
                            2025-05-02